All-trans retinoic acid (ATRA) has been associated with various physiological phenomenon in mammalian adipose tissue and skeletal muscle. We hypothesized that ATRA may affect skeletal muscle fiber type in bovine satellite cell culture through various transcriptional processes. Bovine primary satellite cell (BSC) culture experiments were conducted to determine dose effects of ATRA on expression of genes and protein levels related to skeletal muscle fiber type and metabolism. The semimembranosus from crossbred steers (n = 2 steers), aged approximately 24 months, were used to isolate BSC for 3 separate assays. Myogenic differentiation was induced using 3% horse serum upon cultured BSC with increasing doses (0, 1, 10, 100, 1000 nM) of ATRA. After 96 h of incubation, cells were harvested and used to measure the gene expression of protein kinase B (Akt), AMP-activated protein kinase alpha (AMPK), glucose transporter 4 (GLUT4), myogenin, lipoprotein lipase (LPL), myosin heavy chain (MHC) I, MHC IIA,MHC IIX, insulin like growth factor -1 (IGF-1), Peroxisome proliferator activated receptor gamma (PPARγ), PPARδ, and Smad transcription factor 3 (SMAD3) mRNA relative to ribosomal protein subunit 9 (RPS9). The mRNA expression of LPL was increased (P < 0.05) with 100 and 1000nM of ATRA. Expression of GLUT4 was altered (P < 0.05) by ATRA. The treatment of ATRA (1000nM) also increased (P < 0.05) mRNA gene expression of SMAD3. The gene expression of both PPARδ and PPARγ were increased (P < 0.05) with 1000nM of ATRA. Protein level of PPARδ was also affected (P < 0.05) by 1000nM of ATRA and resulted in a greater (P < 0.05) protein level of PPARδ compared to CON. All-trans retinoic acid (10nM) increased gene expression of MHC I (P < 0.05) compared to CON. Expression of MHC IIA was also influenced (P < 0.05) by ATRA. The mRNA expression of MHC IIX was decreased (P < 0.05) with 100 and 1000nM of ATRA. In muscle cells, ATRA may cause muscle fibers to transition towards the MHC isoform that prefers oxidative metabolism, as evidenced by increased expression of genes associated with the MHC I isoform. These changes in MHC isoforms appeared to be brought about by changing PPARδ gene expression and protein levels.

Objective: Our study aimed to investigate the effects of a 2% increase in dietary total digestible nutrients (TDN) value during the growing (7 to 12 mo of age) and fattening (13 to 30 mo of age) period of Hanwoo steers.Methods: Two hundred and twenty Hanwoo steers were assigned to one of two treatments: i) a control group (basal TDN, BTDN, n = 111 steers, growing = 70.5%, early fattening = 71.0%, late fattening = 74.0%) or high TDN (HTDN, n = 109 steers, growing = 72.6%, early = 73.1%, late = 76.2%). Growth performance, carcass traits, blood parameters, and gene expression of longissimus dorsi (LD) (7, 18, and 30 mo) were quantified.Results: Steers on the BTDN diets had increased (p≤0.02) DMI throughout the feeding trial compared to HTDN, but gain did not differ appreciably. A greater proportion of cattle in HTDN received Korean quality grade 1 (82%) or greater compared to BTDN (77%), while HTDN had a greater yield grade (29%) than BTDN (20%). Redness (a*) of LD muscle was improved (p = 0.021) in steers fed HTDN. Feeding the HTDN diet did not alter blood parameters. Steers fed HTDN diet increased (p = 0.015) the proportion of stearic acid and tended to alter linoleic acid. Overall, saturated, unsaturated, monounsaturated, and polyunsaturated fatty acids of LD muscle were not impacted by the HTDN treatment. A treatment by age interaction was noted for mRNA expression of myosin heavy chain (MHC) IIA, IIX, and stearoyl CoA desaturase (SCD) (p≤0.026). No treatment effect was detected on gene expression from LD muscle biopsies at 7, 18, and 30 mo of age; however, an age effect was detected for all variables measured (p≤0.001).Conclusion: Our results indicated that feeding HTDN diet could improve overall quality grade while minimum effects were noted in gene expression, blood parameters, and growing performance. Cattle performance prediction in the feedlot is a critical decisionmaking tool for optimal planning of cattle fattening and these data provide both benchmark physiological parameters and growth performance measures for Hanwoo cattle feeding enterprises.

Camelina sativa is an annual oilseed crop that requires low inputs. Recently, interest in camelina oil for both human use and biofuel production has increased. Camelina oil extraction is performed through two main methods, namely, mechanical expulsion and solvent extraction. The resulting meals from the oil extraction process show promise as an animal feed due to their high crude protein content. Solvent extraction removes more oil from the seed, which results in a meal that is lower in fat and higher in crude protein concentration than expelled meal (3.52 vs. 13.69% and 41.04 vs. 34.65%, respectively). Solvent-extracted camelina meal has a similar chemical composition to canola meal but less crude protein and more fiber than soybean meal. Camelina meal is also limited by its anti-nutritional factors, mainly glucosinolates. Camelina meal contains 23.10 to 44.90 mmol/kg of glucosinolates, but processing methods may be able to decrease the total glucosinolates. Heat-treating the camelina meal can decrease glucosinolates and remove residual solvent in the solvent-extracted meal. The fungal fermentation of canola meal has also decreased glucosinolates, which could be used in camelina meal as well. The selective breeding of camelina varieties to decrease glucosinolates in the plant is also a solution to the high glucosinolates found in camelina meal. Current feed regulations in the US and Canada limit camelina meal to 10% inclusion in broiler chicken, laying hen, and cattle diets.

Randomized complete block design experiments (n = 6 experiments) evaluating steroidal implants (all from Merck Animal Health, Madison, NJ) were conducted in large-pen feedlot research facilities between 2015 and 2018 comparing an 80 mg trenbolone acetate (TBA) and 8 mg estradiol-17β (E₂) initial implant (Revalor-IH) and reimplanted with 200 mg TBA and 20 mg E₂ (Revalor-200; REPEATED) to a single 80 mg TBA and 8 mg E₂ uncoated; 120 mg TBA and 12 mg E₂ coated implant (Revalor-XH) at arrival (SINGLE) on growth and carcass responses in finishing heifers. Experiments occurred in Nebraska, Oklahoma, Washington, and Texas. Similar arrival processing was used across experiments where 17,675 heifers [initial body weight = 333 kg SEM (4.1)] were enrolled into 180 pens (90 pens per treatment with 65–240 heifers per pen) and fed for 145–222 d. Only REPEATED heifers were removed from their pen at reimplant. Diets contained monensin and tylosin, consisted of ingredients common to each region, and contained greater than 90% concentrate. Ractopamine hydrochloride was fed for a minimum of 28 d prior to harvest. Linear mixed models were used for all analyses; model-adjusted means for each implant group and the corresponding SEM were generated. Distributions of U.S. Department of Agriculture (USDA) quality grade (QG) and yield grade (YG) were analyzed as ordinal outcomes. No differences (P ≥ 0.11) were detected for any performance parameters except dry matter intake (DMI), where SINGLE had greater (P = 0.02) DMI (9.48 vs. 9.38 ± 0.127 kg) compared with REPEATED. Heifers implanted with REPEATED had greater (P ≤ 0.02) hot carcass weight (HCW; 384 vs. 382 ± 2.8 kg), dressing percentage (64.54 vs. 64.22 ± 0.120%), and ribeye area (91.87 vs. 89.55 ± 0.839 cm²) but less (P ≤ 0.01) rib fat (1.78 vs. 1.83 ± 0.025 cm) and calculated YG (2.82 vs. 2.97 ± 0.040) and similar (P = 0.74) marbling scores (503 vs. 505 ± 5.2) compared with SINGLE heifers. Distributions of USDA YG and QG were impacted (P ≤ 0.03) by treatment such that REPEATED had fewer USDA Prime and YG 4 and 5 carcasses. Heifer growth performance did not differ between implant regimens, but HCW and muscling did, perhaps indicating that REPEATED may be suited for grid-based marketing, and SINGLE might be suited for heifers sold on a live basis depending upon market conditions and value-based grid premiums and discounts. However, these decisions are operational dependent and also may be influenced by factors including animal and employee safety, stress on animals, processing facilities, time of year, labor availability, and marketing strategies.

Two experiments evaluated the effect of implant number, type, and total steroidal dose on live animal performance and carcass traits in heifers fed for three different days on feed (DOF). In experiment 1, heifers (n = 3,780; 70 heifers/pen and 9 pens/treatment; initial body weight [BW] = 309 kg) were used in a 2 × 3 factorial arrangement of treatments. Factors were as follows: 1) implant (all from Merck Animal Health, De Soto, KS): 200 mg trenbolone acetate (TBA) and 20 mg estradiol-17β (E₂) administered on arrival (SINGLE), or 80 mg TBA and 8 mg E₂ administered on arrival followed by 200 mg TBA and 20 mg E₂ after approximately 90 d (REPEATED) and 2) duration of DOF: harvested after approximately 172, 193, and 214. In experiment 2, heifers (n = 3,719; 65 to 70 heifers/pen and 9 pens/treatment; initial BW = 337 kg) were used with the same factors as experiment 1, except DOF were 150, 171, and 192. No implant × DOF interaction (P ≥ 0.06) was noted for any performance parameters in either experiment. Heifers administered REPEATED had improved (P ≤ 0.05) live gain to feed ratio (G:F) and carcass-adjusted G:F and tended (P = 0.09) to have greater hot carcass weight (HCW) in experiment 1. Increasing DOF resulted in greater (P ≤ 0.01) live and carcass-adjusted final BW and decreased (P = 0.01) live ADG in experiment 1. As DOF increased, HCW, HCW gain, and dressing% (P ≤ 0.01) increased in experiment 1. The mean carcass transfer was 79.6% across the 42 d terminal window in experiment 1. In experiment 2, REPEATED had improved (P = 0.03) carcass-adjusted G:F compared with SINGLE, but HCW was not different (P = 0.36) between treatments. Increased DOF resulted in greater (P ≤ 0.01) final live and carcass-adjusted BW, decreased (P ≤ 0.01) live and carcass-adjusted ADG, and poorer (P ≤ 0.01) live and carcass-adjusted G:F in experiment 2. In experiment 2, dressing percentage was greater (P = 0.02) in REPEATED compared with SINGLE. Heifers given SINGLE had greater (P = 0.01) back fat and estimated empty body fat (EBF), whereas REPEATED had fewer (P = 0.01) Yield Grade 4 carcasses and greater (P = 0.01) longissimus muscle (LM) area. Increased DOF resulted in greater (P ≤ 0.04) HCW, HCW gain, dressing%, back fat, LM area, marbling, EBF%, and United States Department of Agriculture (USDA) Prime-grading carcasses, Yield Grade 4 and 5, and over 454-kg carcasses in experiment 2. Carcass ADG and carcass transfer indicate a 0.70 kg carcass ADG between 150 and 192 DOF, resulting in an average carcass transfer of 72.2% in experiment 2. Although feedlot growth performance and HCW did not differ between the implant regimens tested, increasing DOF resulted in decreased live growth performance while increasing the proportion of USDA prime carcasses and HCW.

Two studies were conducted to evaluate the effect of encapsulated methionine on live performance, carcass characteristics, and skeletal muscle development in feedlot steers. In Experiment 1, 128 crossbred steers (body weight [BW] = 341 ± 36.7 kg) were used in a randomized complete block design and supplemented with 0, 4, 8, or 12 g/(head day [d]) of ruminally protected methionine (0MET, 4MET, 8MET, and 12MET, respectively) for 111 d or 139 d. In Exp. 2, 20 steers (BW = 457 ± 58 kg) were stratified by BW and randomly assigned to either the 0MET or 8MET treatment; longissimus muscle (LM) biopsies were collected on d 0, 14, 28, 42, and 56, and analyzed for mRNA and protein expression. Additionally, immunohistochemical analysis was performed to measure fiber type area and distribution as well as the density of muscle nuclei and satellite cells (Myf5, Pax7, and Myf5/Pax7). In Experiment 1, no significant differences were observed for live performance (p ≥ 0.09). There was, however, a linear relationship between LM area and methionine supplementation (p = 0.04), with a 9% increase in the area when steers were supplemented with 12MET compared to 0MET. In Exp. 2, There were no treatment × day interactions (p ≥ 0.10) for expression of mRNA or protein abundance. Although mRNA expression and protein abundance of all genes were influenced by day (p ≤ 0.04), methionine supplementation did not have a significant effect (p ≥ 0.08). There was a significant treatment × day interaction for distribution of MHC-I fibers (p = 0.03), where 8MET supplemented cattle had a greater proportion of MHC-I fibers after 56 d of supplementation than did 0MET steers. Cross-sectional area was increased over time regardless of fiber type (p < 0.01) but was unaffected by treatment (p ≥ 0.36). While nuclei density was not impacted by treatment (p = 0.55), the density of myonuclei increased nearly 55% in 8MET supplemented cattle (p = 0.05). The density of Myf5 positive satellite cells tended to decrease with methionine supplementation (p = 0.10), while the density of Pax7 expressing cells tended to increase (p = 0.09). These results indicate that encapsulated methionine supplementation may influence markers of skeletal muscle growth, and potential improvements in the LM area may exist.